Artemether-Lumefantrine: An Option for Malaria

@article{Stover2012ArtemetherLumefantrineAO,
  title={Artemether-Lumefantrine: An Option for Malaria},
  author={Kayla R. Stover and S. Travis King and Jessica Robinson},
  journal={Annals of Pharmacotherapy},
  year={2012},
  volume={46},
  pages={567 - 577}
}
Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of artemether-lumefantrine for the treatment of Plasmodium falciparum malaria. Data Sources: English-language articles indexed in PubMed (1947-November 2011) were identified, using the search terms artemether-lumefantrine, artemether-lumefantrine AND malaria, Coartem, and Coartem AND malaria. Study Selection and Data Extraction: Available English-language articles were reviewed. In addition, the malaria treatment… 

Figures and Tables from this paper

Therapeutic Efficacy of Artemether-Lumefantrine (Coartem®) for the Treatment of Uncomplicated Falciparum Malaria in Africa: A Systematic Review
TLDR
Artemether-lumefantrine remains effective and thus could continue to be the drug of choice for the treatment of uncomplicated falciparum malaria for all age groups in Africa, however, the risk of new emerging resistance for this combination warrants regular monitoring of its efficacy across the continent.
From DEPARTMENT OF PHYSIOLOGY AND PHARMACOLOGY Karolinska Institutet, Stockholm, Sweden SEARCH FOR GENETIC DETERMINANTS OF PLASMODIUM FALCIPARUM MALARIA DRUG RESISTANCE IN VITRO AND IN VIVO
TLDR
An explorative study based on the determination of the in vitro sensitivity of 47 culture adapted parasites from Mae Sot (Thai-Myanmar boarder) to a number of ACT drugs, revealing two novel candidate markers of multidrug resistance.
Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine
TLDR
Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least pfcrt K76T and pfmdr1 N86Y should now be routine.
Management and Control of Antimalarial Drug Resistance
TLDR
The demographical distribution of malaria throughout the world along with its clinical manifestations is discussed and effect of wide spectrum usage of antimalarials and combinational therapy against the deadly disease is described.
WWARN AL, (2014) Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for P. falciparum Malaria after Artemether-
TLDR
Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least pfcrtK76T and pfmdr1N86Y should now be routine.
Safety Assessment of Artemether/Lumefantrine/ Tinidazole on the Kidneys of Healthy and Diseased Mice
TLDR
The use of A/L/T as an antimalarial drug may be safe on the kidney, but long term use may cause kidney damage.
Charles Darwin University Polymorphisms in Plasmodium falciparum chloroquine Resistance Transporter and Multidrug Resistance 1 Genes Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine Venkatesan,
TLDR
Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least pfcrtK76T and pfmdr1N86Y should now be routine.
Will the novel antimalarial agent DDD107498 that selectively targets translation elongation factor 2 show good efficacy and safety in future clinical trials
TLDR
DDD107498, a new experimental antimalarial agent, has been developed and shown strong potency, good pharmacokinetic properties, and acceptable safety profiles in preclinical models and is expected that it will be used in combination with another approved anti-parasitic drug to fight against malaria.
Nanomedicine against malaria.
TLDR
Methods for the diagnosis of malaria can benefit from nanotools applied to the design of microfluidic-based devices for the accurate identification of the parasite's strain, its precise infective load, and the relative content of the different stages of its life cycle, whose knowledge is essential for the administration of adequate therapies.
Antimalarial combination therapies increase gastric ulcers through an imbalance of basic antioxidative-oxidative enzymes in male Wistar rats
TLDR
Investigation of the effects of Artesunate-Amodiaquine and Artemether-Lumefantrine on ulcer induction demonstrated a need to revisit information on the pharmacodynamics of major circulating antimalarial agents in developing countries.
...
...

References

SHOWING 1-10 OF 97 REFERENCES
The clinical efficacy of artemether/lumefantrine (Coartem®)
TLDR
The efficacy of the six-dose regimen of artemether/lumefantrine has been confirmed in many different patient populations around the world, consistently achieving 28-day PCR-corrected cure rates of >95% in the evaluable population, rapidly clearing parasitaemia and fever, and demonstrating a significant gametocidal effect, even in areas of widespread parasite resistance to other antimalarials.
A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy
TLDR
The current standard six-dose artemether-lumefantrine regimen was well tolerated and safe in pregnant Karen women with uncomplicated falciparum malaria, but efficacy was inferior to 7 d artesunate monotherapy and was unsatisfactory for general deployment in this geographic area.
Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria
TLDR
The status of clinical pharmacology, efficacy and real-life effectiveness of AL under a variety of settings are focused on, and some of the challenges that face policy makers during the deployment of AL are highlighted with regards to ensuring that those who most need this therapy will not be denied access due to official inefficiency in procurement and distribution processes.
Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan
TLDR
The findings showed that artemether-lumefantrine was an effective and safe drug for treating uncomplicated P. falciparum malaria in northern and southern Sudan.
Coartem®: the journey to the clinic
TLDR
The combination of artemether and lumefantrine reduces the risk of resistance developing to either agent, and to date there are no reports of resistance to AL combined therapy in the malaria parasite that infects humans.
Therapeutic efficacy of artemether-lumefantrine in uncomplicated falciparum malaria in India
TLDR
AL is safe and effective drug for the treatment of acute uncomplicated falciparum malaria in India and can be a viable alternative of artesunate plus sulphadoxine/pyrimethamine (AS + SP), however, the drug should be used rationally and efficacy needs to be monitored periodically.
Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial
TLDR
DHA-PQP is as efficacious as AL in treating uncomplicated malaria in African children from different endemicity settings, and shows a comparable safety profile.
First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria.
TLDR
The first case of such treatment failure of imported malaria in Japan in a 58-year-old Japanese man who showed recrudescence of Plasmodium falciparum after treatment with artemether-lumefantrine is reported.
Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine
TLDR
Characterisation of these pharmacokinetic-pharmacodynamic relationships provided the basis for dosage optimisation, an approach that could be applied to other antimalarial drugs.
Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon
TLDR
Although AM-LM requires six doses, rather than three doses for other artemisinin-based combinations, it has potential advantages over other forms of ACT, and suggested that artesunate-amodiaquine (AS-AQ) is as effective as other drugs.
...
...